The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies
Open accessAbstract
Parkinson's disease (PD) is one of the most common neurodegenerative diseases. It is characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta of the brain. Another feature is represented by the formation in these cells of inclusions called Lewy bodies (LB), principally constituted by fibrillar α-synuclein (αSyn). This protein is considered a key element in the aetiology of a group of neurodegenerative disorders termed synucleinopathies, which include PD, but the cellular and molecular mechanisms involved are not completely clear. It is established that the inflammatory process plays a crucial role in the pathogenesis and/or progression of PD; moreover, it is known that aggregated αSyn, released by neurons, activates microglia cells to produce pro-inflammatory mediators, such as IL-1β. IL-1β is one of the strongest pro-inflammatory cytokines; it is produced as an inactive mediator, and its maturation and activation requires inflammasome activation. In particular, the NLRP3 inflammasome is activated by a wide variety of stimuli, among which are crystallized and particulate material. In this work, we investigated the possibility that IL-1β production, induced by fibrillar αSyn, is involved the inflammasome activation. We demonstrated the competence of monomeric and fibrillar αSyn to induce synthesis of IL-1β, through TLR2 interaction; we found that the secretion of the mature cytokine was a peculiarity of the fibrillated protein. Moreover, we observed that the secretion of IL-1β involves NLRP3 inflammasome activation. The latter relies on the phagocytosis of fibrillar αSyn, followed by increased ROS production and cathepsin B release into the cytosol. Taken together, our data support the notion that fibrillar αSyn, likely released by neuronal degeneration, acts as an endogenous trigger inducing a strong inflammatory response in PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an in vitro experiment, both monomeric and fibrillary α-synuclein can stimulate TLR2 and induce the expression of pro-IL-1β, but only fibrillary α-synuclein can activate the NLRP3 inflammasome, resulting in the secretion of active IL-1β.358”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [358]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting caspase-1, a downstream molecule of NLRP3, is another promising method, which was found to decrease the secretion of IL-1β and attenuate the susceptibility of dopaminergic neurons.358”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [358]
Experimental — accuracy not yet measuredIn the citing paper
“The fibrillar, but not monomeric, form of α-synuclein induced NLRP3- and caspase-1–mediated IL-1β secretion in human monocytes and BV2 microglial cell line (238), or via TLR-2 signaling pathway in rodents microglial cells (250).”
From The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology (2020) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Protein Misfolding, Functional Amyloid, and Human Disease
Chiti, F., & Dobson, C. M. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.101304.123901 · Cited by 6,497
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Schroder, K., & Tschopp, J. (2010) · Cell · doi:10.1016/j.cell.2010.01.040 · Cited by 5,475
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Cited by
Sorted by citations
Items 301–400 of 587
Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
Lai, T. T., Kim, Y. J., Ma, H.-I., & Kim, Y. E. (2022) · Journal of Movement Disorders · doi:10.14802/jmd.21078 · Cited by 32
Hamzeh, O., Rabiei, F., Shakeri, M., Parsian, H., Saadat, P., & Rostami-Mansoor, S. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.10.003 · Cited by 32
Chen, C., Yen, C.-Y., Chen, W.-L., Lin, C., Wu, Y., Chang, K., & Lee‐Chen, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031062 · Cited by 31
The Significance of NLRP Inflammasome in Neuropsychiatric Disorders
Shen, Y., Qian, L., Luo, H., Li, X., Ruan, Y., Fan, R., Si, Z., Chen, Y.-P., Li, L., & Liu, Y. (2022) · Brain Sciences · doi:10.3390/brainsci12081057 · Cited by 32
Cao, X., Ge, S., Chen, M., Mao, H., & Wang, Y. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c00103 · Cited by 31
Michaelson, N. M., Facciponte, D. N., Bradley, W. G., & Stommel, E. W. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.05.001 · Cited by 33
Role of NLRP3 in Parkinson's disease: Specific activation especially in dopaminergic neurons
Yu, J., Zhao, Z., Li, Y., Chen, J., Huang, N., & Luo, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28838 · Cited by 32
Caspases orchestrate microglia instrumental functions
Shen, X., Venero, J. L., Joseph, B., & Burguillos, M. Á. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.007 · Cited by 31
Yazar, H. O., Yazar, T., & Cihan, M. (2019) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2019.08.032 · Cited by 30
Deciphering variability in the role of interleukin-1β in Parkinson’s disease
Saghazadeh, A., Ferrari, C. C., & Rezaei, N. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0059 · Cited by 30
Ma, Q., & Lim, C. S. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031023-125300 · Cited by 36
Redenšek, S., Flisar, D., Kojović, M., Kramberger, M. G., Georgiev, D., Pirtošek, Z., Trošt, M., & Dolžan, V. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1439-y · Cited by 29
Harrison, D., Bock, M. G., Doedens, J. R., Gabel, C. A., Holloway, M. K., Lewis, A., Scanlon, J., Sharpe, A., Simpson, I. D., Smolak, P. J., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.2c00242 · Cited by 29
Targeting the inflammasome in Parkinson’s disease
Su, Q., Ng, W. L., Goh, S. Y., Gulam, M. Y., Wang, L., Tan, E., Ahn, M., & Chao, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.957705 · Cited by 31
Hou, L., Liu, J., Sun, F., Huang, R., Chang, R., Ruan, Z., Wang, Y., Zhao, J., & Wang, Q. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02732-x · Cited by 30
Pyroptosis in neurodegenerative diseases: from bench to bedside
Wu, K., Wang, W.-R., Cheng, Q.-H., Li, H., Yan, W.-Z., Zhou, F.-R., & Zhang, R. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09820-x · Cited by 32
Yang, H., Shao, Y., Hu, Y., Jin, Q., Wang, P., Tian, L., Ni, Y., Li, S., Al‐Nusaif, M., Liu, C., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70003 · Cited by 33
Candidate genes for Parkinson disease: Lessons from pathogenesis
Rosa, P. D., Marini, E. S., Gelmetti, V., & Valente, E. M. (2015) · Clinica Chimica Acta · doi:10.1016/j.cca.2015.04.042 · Cited by 29
Anti-NLRP3 Inflammasome Natural Compounds: An Update
Liu, B., & Yu, J. (2021) · Biomedicines · doi:10.3390/biomedicines9020136 · Cited by 31
Discovery and characterization of small-molecule inhibitors of NLRP3 and NLRC4 inflammasomes
Sebastian-Valverde, M., Wu, H. D., Rahim, M. A., Sánchez, R., Kumar, K., Vita, R. J. D., & Pasinetti, G. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100597 · Cited by 30
Negrini, M., Tomasello, G., Davidsson, M., Fenyi, A., Adant, C., Hauser, S., Espa, E., Gubinelli, F., Manfredsson, F. P., Melki, R., et al. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-212555 · Cited by 27
Zhang, R., Chen, X., Cheng, Y., Chen, Z., Li, X., & Deng, Y. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215616 · Cited by 27
Mechanisms and therapeutic potential of pharmacological agents targeting inflammasomes
Li, H., Liu, T., Shi, X., Du, H., Cai, C., Yang, D., Qu, L., Dou, H., Jiao, B., & Jiao, B. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118164 · Cited by 29
An association between mitochondria and microglia effector function: what do we think we know?
Harry, G. J., Childers, G. M., Giridharan, S., & Hernandes, I. L. (2020) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2020.07 · Cited by 27
Ho, D. H., Nam, D., Seo, M. K., Park, S., Seol, W., & Son, I. (2022) · Cells · doi:10.3390/cells11050861 · Cited by 27
Microglial activation in Alzheimer's disease: The role of flavonoids and microRNAs
Medrano-Jiménez, E., Meza‐Sosa, K. F., Aragon, J. A. U., Secundino, I., Pedraza-Alva, G., & Pérez-Martínez, L. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr1021-531r · Cited by 28
Yan, Y., Pu, J., Zheng, R., Fang, Y., Gu, L., Guo, T., Si, X., Zhou, C., Chen, Y., Liu, Y., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15537 · Cited by 28
New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease
Tan, J. S. Y., Chao, Y., Rötzschke, O., & Tan, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239302 · Cited by 27
Yang, X., Huang, J.-H., Ye, F., Yv, Q., Chen, S., Li, W.-W., & Zhu, M. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.155230 · Cited by 29
Prelysosomal Compartments in the Unconventional Secretion of Amyloidogenic Seeds
Madsen, H. B., & Vilhardt, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010227 · Cited by 26
Monocyte biomarkers define sargramostim treatment outcomes for Parkinson's disease
Abdelmoaty, M. M., Machhi, J., Yeapuri, P., Shahjin, F., Kumar, V. S., Olson, K. E., Mosley, R. L., & Gendelman, H. E. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.958 · Cited by 25
NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP
Chen, Y., Zhang, Q.-S., Shao, Q.-H., Wang, S., Yuan, Y., Chen, N., & Wang, H. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-018-0209-1 · Cited by 26
Is Targeting the Inflammasome a Way Forward for Neuroscience Drug Discovery?
Swanton, T., Cook, J., Beswick, J. A., Freeman, S., Lawrence, C. B., & Brough, D. (2018) · SLAS DISCOVERY · doi:10.1177/2472555218786210 · Cited by 26
von Herrmann, K. M., Anderson, F. L., Martinez, E. M., Young, A. L., & Havrda, M. C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01866-6 · Cited by 25
Liu, L., Zhou, T., Li, T., Liang, Z., & Luo, X. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113923 · Cited by 25
Interplay between Mitophagy and Inflammasomes in Neurological Disorders
Kesharwani, R., Sarmah, D., Kaur, H., Mounika, L., Verma, G., Veeresh, P., Kotian, V., Kalia, K., Borah, A., Dave, K. R., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00117 · Cited by 25
Hippocampal proliferation is increased in presymptomatic Parkinson’s disease and due to microglia
Doorn, K. J., Drukarch, B., van Dam, A.-M., & Lucassen, P. J. (2014) · Neural Plasticity · doi:10.1155/2014/959154 · Cited by 24
Revisiting the critical roles of reactive microglia in traumatic brain injury
Zhao, J., Zhou, Y., Zhou, C.-W., Zhan, K., Yang, M., Wen, M., & Zhu, L. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002420 · Cited by 30
The role of Alu-derived RNAs in Alzheimer’s and other neurodegenerative conditions
Polesskaya, O., Kananykhina, E. Y., Roy‐Engel, A. M., Nazarenko, O., Kulemzina, I. A., Baranova, A. V., Vassetzky, Y. S., & Myakishev-Rempel, M. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.03.008 · Cited by 23
Molecular biology of autoinflammatory diseases
Masumoto, J., Zhou, W., Morikawa, S., Hosokawa, S., Taguchi, H., Yamamoto, T., Kurata, M., & Kaneko, N. (2021) · Inflammation and Regeneration · doi:10.1186/s41232-021-00181-8 · Cited by 26
Cheon, S. Y., Kim, J., Kim, S. Y., Kim, E. J., & Koo, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031103 · Cited by 24
Emerging preclinical pharmacological targets for Parkinson's disease
More, S. V., & Choi, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8104 · Cited by 24
Francelle, L., & Mazzulli, J. R. (2022) · Brain Research · doi:10.1016/j.brainres.2022.147798 · Cited by 23
Revisiting Alpha-Synuclein Pathways to Inflammation
Lyra, P., Machado, V., Rota, S., Chaudhuri, К. R., Botelho, J., & Mendes, J. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087137 · Cited by 24
Moghaddam, S. A., Pourabdolhossein, F., Najafzadehvarzi, H., Sarbishegi, M., Saleki, K., & Nouri, H. R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25523 · Cited by 25
Mural Cells: Potential Therapeutic Targets to Bridge Cardiovascular Disease and Neurodegeneration
Lin, A., Peiris, N. J., Dhaliwal, H., Hakim, M., Li, W., Ganesh, S., Ramaswamy, Y., Patel, S., & Misra, A. (2021) · Cells · doi:10.3390/cells10030593 · Cited by 24
Overview of the Gut–Brain Axis: From Gut to Brain and Back Again
Post, Z., Manfready, R. A., & Keshavarzian, A. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771464 · Cited by 25
Carelli, S., Giallongo, T., Gombalová, Z. T., Rey, F., Gorio, M. C., Mazza, M., & Giulio, A. M. D. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1375-2 · Cited by 22
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
Grimmig, B., Morganti, J., Nash, K., & Bickford, P. (2016) · Brain Sciences · doi:10.3390/brainsci6040041 · Cited by 17
Marchetti, B., Giachino, C., Tirolo, C., & Serapide, M. F. (2022) · Aging Cell · doi:10.1111/acel.13575 · Cited by 22
How Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis
Zhang, Z., Liu, Z., Lv, A., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154626 · Cited by 21
Zhang, W., Dong, X., & Huang, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106787 · Cited by 22
Ranaldi, E. D. L. R. M. C., Nuytemans, K., Martinez, A., Luca, C. C., Keane, R. W., & Vaccari, J. P. D. R. (2023) · Pharmaceuticals · doi:10.3390/ph16060883 · Cited by 22
Immune system and new avenues in Parkinson’s disease research and treatment
Nasrolahi, A., Safari, F., Farhoudi, M., Khosravi, A., Farajdokht, F., Bastaminejad, S., Shotorbani, S. S., & Mahmoudi, J. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2018-0105 · Cited by 21
Jia, F., Song, N., Zhao, C., Xie, J., & Jiang, H. F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091641 · Cited by 21
A Novel Long-Noncoding RNA LncZFAS1 Prevents MPP+-Induced Neuroinflammation Through MIB1 Activation
Zhu, Z., Huang, P., Sun, R., Li, X., Li, W., & Gong, W. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02619-z · Cited by 20
Mechanisms of NLRP3 activation and pathology during neurodegeneration
Jose, S., Groves, N. J., Roper, K. E., & Gordon, R. (2022) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2022.106273 · Cited by 22
Characterisation of functional deficits induced by AAV overexpression of alpha-synuclein in rats
Gubinelli, F., Sarauskyte, L., Venuti, C., Kulacz, I., Cazzolla, G., Negrini, M., Anwer, D., Vecchio, I., Jakobs, F., Manfredsson, F. P., et al. (2022) · Current Research in Neurobiology · doi:10.1016/j.crneur.2022.100065 · Cited by 21
Sharma, M., Sharma, N., & Khairnar, A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03847-y · Cited by 20
Stress-Induced NLRP3 Inflammasome in Human Diseases
Alcocer‐Gómez, E., Castejón‐Vega, B., & Cordero, M. D. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.02.002 · Cited by 19
NLRP3 inflammasome activation is involved in trimethyltin-induced neuroinflammation
Long, J., Wang, Q., He, H., Sui, X. Y., Lin, G.-D., Wang, S., Yang, J., You, P., Luo, Y., & Wang, Y. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.003 · Cited by 20
Inflammaging as the basis of age-associated diseases
Artemyeva, O. V., & Gankovskaya, L. V. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-iat-1938 · Cited by 21
Sequelae of viral CNS infections including outcomes, mechanisms, and knowledge gaps
Kelly, R., Reinert, L. S., & Paludan, S. R. (2025) · npj Viruses · doi:10.1038/s44298-025-00160-7 · Cited by 21
An overview of disease models for NLRP3 inflammasome over-activation
Zhang, H., Zahid, A., Ismail, H., Tang, Y., Jin, T., & Tao, J. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1844179 · Cited by 20
Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases
Péladeau, C. L., & Sandhu, J. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116068 · Cited by 20
The interplay between neuroinflammatory pathways and Parkinson's disease
Ocak, P. E., Kocabıçak, E., Bekâr, A., & Temel, Y. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114644 · Cited by 20
Salemi, M., Ravo, M., Lanza, G., Schillaci, F. A., Ventola, G. M., Marchese, G., Salluzzo, M. G., Cappelletti, G., & Ferri, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020707 · Cited by 19
Mitochondrion-based organellar therapies for central nervous system diseases
Zhao, M., Wang, J., Zhu, S., Wang, M., Chen, C., Wang, L., & Liu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01843-z · Cited by 21
Pyroptosis and neurological diseases
Zhao, G., & Xie, Z. (2014) · Neuroimmunology and Neuroinflammation · doi:10.4103/2347-8659.139716 · Cited by 19
Targeting α-synuclein as a therapeutic strategy for Parkinson’s disease
Lawand, N., Saadé, N. E., El‐Agnaf, O. M. A., & Safieh‐Garabedian, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1062877 · Cited by 19
Ivanidze, J., Skafida, M., Pandya, S., Patel, D., Osborne, J. R., Raj, A., Gupta, A. K., Henchcliffe, C., & Dyke, J. P. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.528809 · Cited by 18
Zhao, R., Mu, B., Wang, D., XinHuang, Ma, Q., & Lu, M. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-04584-9 · Cited by 24
Mammoliti, O., Carbajo, R. J., Pérez‐Benito, L., Yu, X., Prieri, M., Bontempi, L., Embrechts, S., Paesmans, I., Bassi, M., Bhattacharya, A., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c03108 · Cited by 18
Pons-Espinal, M., Blasco-Agell, L., & Consiglio, A. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03700-x · Cited by 18
Brand-Rubalcava, P. A., Tejeda-Martínez, A. R., González‐Reynoso, O., Nápoles-Medina, A. Y., Chaparro-Huerta, V., & Flores-Soto, M. E. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105906 · Cited by 18
Effects of exercise on neuroinflammation in age-related neurodegenerative disorders
Su, Y., & Su, Z. (2025) · European journal of medical research · doi:10.1186/s40001-025-03165-3 · Cited by 22
Mitochondrial DNA: a molecular switch driving sterile neuroinflammation
Jauhari, A., Singh, T., Carlisle, D. L., & Friedlander, R. M. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00540-w · Cited by 20
Immunological aspects of central neurodegeneration
Niso‐Santano, M., Fuentes, J. M., & Galluzzi, L. (2024) · Cell Discovery · doi:10.1038/s41421-024-00666-z · Cited by 17
Modulation of Innate Immunity by Amyloidogenic Peptides
Westwell-Roper, C. Y., & Verchere, C. B. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.005 · Cited by 17
Khan, A., Johnson, R., Wittmer, C., Maile, M., Tatsukawa, K. J., Wong, J. L., Gill, M. B., Stocking, E. M., Natala, S. R., Paulino, A., et al. (2021) · Brain · doi:10.1093/brain/awab214 · Cited by 17
Kim, J. H., Park, J. H., Eisenhut, M., Yu, J., & Shin, J. I. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.05.018 · Cited by 18
Natural products: An emerging tool in parkinson’s disease therapeutics
Desai, S. R., Doke, R. R., Pansare, P. A., Sainani, S. R., & Bhalchim, V. M. (2019) · IP Indian Journal of Neurosciences · doi:10.18231/j.ijn.2019.014 · Cited by 17
Ding, J., Shen, L., Ye, Y., Hu, S., Ren, Z., Liu, T., Dai, J., Li, Z., Wang, J., Luo, Y., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.861340 · Cited by 16
Gao, X., Wang, L., Lü, X., Yan, Y., Guo, Y., Wang, J., Li, L., & Dong, K. (2023) · American Journal Of Pathology · doi:10.1016/j.ajpath.2023.06.011 · Cited by 16
Shateri, S., Khatami, S. H., Toutounchi, A. H., Rajaei, S., Mahdavi, M., Baram, S. M., Shahidi, G. A., Habibi, A. H., Aghamollaii, V., Ghlichnia, B., et al. (2023) · International Journal of Neuroscience · doi:10.1080/00207454.2023.2292951 · Cited by 16
Shared Inflammatory Pathology of Stroke and COVID-19
Sánchez, K. E., & Rosenberg, G. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095150 · Cited by 16
Rani, L., Sahu, M. R., & Mondal, A. C. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.07.007 · Cited by 16
Inflammasome activation and assembly in Huntington’s disease
Furlam, T. D. O., Roque, I. G., da Silva, E. W. M., Vianna, P. P., Valadão, P. A. C., Guatimosim, C., Teixeira, A. L., & de Miranda, A. S. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.09.002 · Cited by 16
Chen, Y.-F., Bian, J., Zhang, P., Bu, L.-L., Shen, Y., Yu, W., Lu, X., Lin, X., Ye, D., Wang, J., et al. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115358 · Cited by 16
Araújo, F. M. D., Frota, A. F., de Jesus, L. B., Macedo, T. C., Cuenca‐Bermejo, L., Sanchez-Rodrigo, C., Ferreira, K. M. S., de Oliveira, J. V. R., Costa, M. D. F. D., Segura-Aguilar, J., et al. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01173-5 · Cited by 15
Clinical Trial Highlights: Anti-Inflammatory and Immunomodulatory Agents
Patel, B., Greenland, J. C., & Williams‐Gray, C. H. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240353 · Cited by 20
Gao, Q., Camous, X., Lu, Y., Lim, M.-L., Larbi, A., & Ng, T. P. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.12.002 · Cited by 15
Bonte, M.-A., Idrissi, F. E., Gressier, B., Devos, D., & Bélarbi, K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107526 · Cited by 17
Polazzi, E., Mengoni, I., Peña‐Altamira, E., Massenzio, F., Virgili, M., Petralla, S., & Monti, B. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000222 · Cited by 16
Mercado, G., Käufer, C., Richter, F., & Peelaerts, W. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240195 · Cited by 16
Therapeutic potential of baicalein against neurodegenerative diseases: An updated review
Siddiqui, N., Talib, M., Tripathi, P. N., Kumar, A., & Sharma, A. K. (2024) · Health Sciences Review · doi:10.1016/j.hsr.2024.100172 · Cited by 15
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Stott, S., Wyse, R. K. H., & Brundin, P. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.007 · Cited by 16
Status and future directions of clinical trials in Parkinson's disease
Söderbom, G. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.02.009 · Cited by 14
Bearoff, F. M., Dhavale, D. D., Kotzbauer, P. T., & Kortagere, S. (2022) · Molecular Immunology · doi:10.1016/j.molimm.2022.12.006 · Cited by 15
Wang, L., Wang, W., Zhang, L., Dai, P., Wang, K., Hui, H., Rao, W., Peng, C., Yang, J.-H., Yan, Z., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.12.045 · Cited by 14
Metadata
- Authors
- Codolo, G., Plotegher, N., Pozzobon, T., Brucale, M., Tessari, I., Bubacco, L., & de Bernard, M.
- Affiliations
- University of Padua (IT)
- Veneto Institute of Molecular Medicine (IT)
- Institute of Nanostructured Materials (IT)
- Corresponding author
- Bubacco, Luigi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-31
- Volume
- 8
- Issue
- 1
- Pages
- e55375
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3561263
- OpenAlex
- W2015283405
- Cited by
- 585
- References
- 67
- Citations by year
- 2026: 23 · 2025: 38 · 2024: 56 · 2023: 59 · 2022: 68 · 2021: 65 · 2020: 58 · 2019: 53 · 2018: 48 · 2017: 31 · 2016: 27 · 2015: 30 · 2014: 23 · 2013: 5
- FWCI
- 12.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Fondazione Cariplo (2011-0485)
- Università degli Studi di Padova
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- alpha-synuclein aggregation, NLRP3 inflammasome, IL-1β, Parkinson's disease, synucleinopathies, TLR2, microglial activation, phagocytosis, reactive oxygen species, cathepsin B, Lewy bodies, neuroinflammation, neurodegeneration
- MeSH terms
- NLR Family, Pyrin Domain-Containing 3 Protein, Analysis of Variance, Carrier Proteins, Humans, Inflammation, Neurons, Parkinson Disease, Phagocytosis, Spectrometry, Fluorescence, Spectrophotometry, Ultraviolet, Thiazoles, Blotting, Western, Lewy Bodies, DNA Primers, Microscopy, Confocal, Microscopy, Atomic Force, Microscopy, Electron, Transmission, Toll-Like Receptor 2, alpha-Synuclein, Benzothiazoles, Interleukin-1beta, Chromatography, Reverse-Phase, Inflammasomes, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review